BioSpace News Archive

Quotient Limited, a commercial-stage diagnostics company, announced that Peter Buhler has notified the Company that he is resigning from his position as Chief Financial Officer to take a position with another company.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3.82 per share, the closing price of Assembly Bio’s common stock on July 1, 2021.

SANUWAVE Health, Inc., a leading provider of next-generation wound care products has announced that as of July 2, 2021 the company’s shares will no longer be traded on the OTCQB due to failure to timely file quarterly financials with the Securities & Exchange Commission.

SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 34,375 shares of Puma common stock to five new non-executive employees.

Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that its co-development partner, Bharat Biotech, shared positive results of its Phase 3 study of COVAXIN™, a whole virion inactivated COVID-19 vaccine candidate.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.